<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869358</url>
  </required_header>
  <id_info>
    <org_study_id>COMB157GDE01</org_study_id>
    <nct_id>NCT04869358</nct_id>
  </id_info>
  <brief_title>Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab</brief_title>
  <acronym>KYRIOS</acronym>
  <official_title>Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to understand whether patients with MS can mount an immune response to&#xD;
      SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either&#xD;
      before initiation of ofatumumab treatment or at least 4 weeks after commencing ofatumumab&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two cohort, multicenter, open-label, prospective study of 40 (optionally up to 60)&#xD;
      patients with relapsing multiple sclerosis (RMS) planning to undergo a SARS-CoV-2 mRNA&#xD;
      vaccination (initial vaccinations or booster vaccines) as part of clinical routine. The&#xD;
      maximal duration of the study for an individual patient is 22 months.&#xD;
&#xD;
        -  The first cohort will be RMS patients receiving SARS-CoV-2 mRNA vaccine (initial&#xD;
           vaccinations or booster vaccines) as part of clinical routine prior to starting&#xD;
           ofatumumab treatment.&#xD;
&#xD;
        -  The second cohort will be participants receiving SARS-CoV-2 mRNA vaccine (initial&#xD;
           vaccinations or booster vaccines) as part of clinical routine while already stable on&#xD;
           ofatumumab treatment for at least 4 weeks (since first dose).&#xD;
&#xD;
      Development of SARS-CoV-2 specific T-cells and functional anti-SARS-CoV-2 antibodies will be&#xD;
      investigated for up to 18 months after the participants' vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of RMS patients having established SARS-CoV-2-specific T cells after receiving a modRNA vaccine</measure>
    <time_frame>at 1 month after second dose of vaccine or booster vaccine</time_frame>
    <description>Detection of SARS-CoV-2 specific T-cells measured at the central laboratory e.g. by enzyme-linked immunosorbent spot (ELIspot) assay from peripheral blood mononuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving seroconversion</measure>
    <time_frame>at baseline, 1 week, 1 , 6, 12 and 18 months after second dose of vaccine or 1,6 and 12 months after booster vaccine</time_frame>
    <description>SARS-CoV-2 neutralizing antibodies measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants maintaining SARS-CoV-2 specific T-cells</measure>
    <time_frame>at baseline, 1 week, 1 , 6, 12 and 18 months after second dose of vaccine or 1,6 and 12 months after booster vaccine</time_frame>
    <description>Maintenance of SARS-CoV-2 specific T-cells over time measured at the central laboratory e.g. by enzyme-linked immunosorbent spot (ELIspot) assay from peripheral blood mononuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells</measure>
    <time_frame>at baseline, 1 week, 1 , 6, 12 and 18 months after second dose of vaccine or 1,6 and 12 months after booster vaccine</time_frame>
    <description>Phenotypic description of the cellular immune response performed at the central laboratory by FACS analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events, serious adverse events and COVID-19 infections</measure>
    <time_frame>Up to 18 months after second dose of vaccine or 12 months after booster vaccine</time_frame>
    <description>Untoward medical occurrences (including abnormal laboratory tests, vital signs and other safety assessments) will be captured as adverse events including COVID-19 infections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Vaccination before treatment initiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive SARS-CoV-2 mRNA vaccines before starting ofatumumab treatment (approx. 1 month later)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccination during treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive SARS-CoV-2 mRNA vaccines while already stable on ofatumumab treatment (at least 4 weeks since first dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter</description>
    <arm_group_label>Vaccination before treatment initiation</arm_group_label>
    <arm_group_label>Vaccination during treatment</arm_group_label>
    <other_name>OMB157</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsing Multiple Sclerosis (RMS) diagnosis&#xD;
&#xD;
          -  eligible for ofatumumab treatment&#xD;
&#xD;
          -  willing and eligible to receive SARS-CoV-2 mRNA vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known prior or current COVID-19 infection&#xD;
&#xD;
          -  previous treatment with BTK inhibitor or anti-CD20 therapy other than ofatumumab&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>D 33647</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Unterhaching</city>
        <zip>82008</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 mRNA vaccine</keyword>
  <keyword>immune response</keyword>
  <keyword>Ofatumumab</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <keyword>RMS</keyword>
  <keyword>adult</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

